Literature DB >> 27139434

Epigenetic changes of CDX2 in gastric adenocarcinoma.

Ali Akbar Samadani1, Novin Nikbakhsh2, Maryam Pilehchian3, Sadegh Fattahi1, Haleh Akhavan-Niaki4,5.   

Abstract

Gastric cancer is one of the most commonplace and lethal cancers in the world. Molecular investigation of this disease, in order to obtain diagnostic and treatments achievements is important and vital. Relatively, in this research study, one of the most important epigenetic factors, the methylation of CDX2 gene was investigated in tumoral and non-tumoral tissues of gastric cancer patients by bisulfite treatment followed by sequencing of the 5'UTR region of CDX2 in both tissues. The results indicated a hypomethylation in tumoral tissues of adenocarcinoma. Consequently, the methylation amount of CDX2 in tumoral tissues was significantly reduced compared with non-tumoral tissues.

Entities:  

Keywords:  CDX2; Gastric cancer; Methylation; UTR

Year:  2016        PMID: 27139434      PMCID: PMC5143315          DOI: 10.1007/s12079-016-0327-9

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  21 in total

Review 1.  Allele-specific DNA methylation: beyond imprinting.

Authors:  Benjamin Tycko
Journal:  Hum Mol Genet       Date:  2010-09-20       Impact factor: 6.150

2.  MiR-9 downregulates CDX2 expression in gastric cancer cells.

Authors:  Pichayanoot Rotkrua; Yoshimitsu Akiyama; Yutaka Hashimoto; Takeshi Otsubo; Yasuhito Yuasa
Journal:  Int J Cancer       Date:  2011-03-25       Impact factor: 7.396

Review 3.  Promoter methylation of tumor-related genes in gastric carcinogenesis.

Authors:  Chenghai Zhao; Xianmin Bu
Journal:  Histol Histopathol       Date:  2012-10       Impact factor: 2.303

4.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.

Authors:  M Esteller; M Toyota; M Sanchez-Cespedes; G Capella; M A Peinado; D N Watkins; J P Issa; D Sidransky; S B Baylin; J G Herman
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

5.  Expression and significance of homeodomain protein Cdx2 in gastric carcinoma and precancerous lesions.

Authors:  Rong Qin; Na-Na Wang; Jing Chu; Xian Wang
Journal:  World J Gastroenterol       Date:  2012-07-07       Impact factor: 5.742

6.  Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells.

Authors:  Tohru Niwa; Tetsuya Tsukamoto; Takeshi Toyoda; Akiko Mori; Harunari Tanaka; Takao Maekita; Masao Ichinose; Masae Tatematsu; Toshikazu Ushijima
Journal:  Cancer Res       Date:  2010-02-02       Impact factor: 12.701

7.  Promoter methylation status of DNA repair gene (hMLH1) in gastric carcinoma patients of the Kashmir valley.

Authors:  Majid Wani; Dil Afroze; Muzamil Makhdoomi; Iqra Hamid; Bilal Wani; Gulzar Bhat; Rauf Wani; Khursheed Wani
Journal:  Asian Pac J Cancer Prev       Date:  2012

8.  Helicobacter pylori and the BMP pathway regulate CDX2 and SOX2 expression in gastric cells.

Authors:  Vânia Camilo; Rita Barros; Sofia Sousa; Ana Maria Magalhães; Teresa Lopes; António Mário Santos; Teresa Pereira; Céu Figueiredo; Leonor David; Raquel Almeida
Journal:  Carcinogenesis       Date:  2012-07-12       Impact factor: 4.944

9.  CDX1 and CDX2 expression in intestinal metaplasia, dysplasia and gastric cancer.

Authors:  Jung Mook Kang; Byoung Hwan Lee; Nayoung Kim; Hye Seung Lee; Hee Eun Lee; Ji Hyun Park; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  J Korean Med Sci       Date:  2011-04-21       Impact factor: 2.153

10.  Analyses of methylation status of CpG islands in promoters of miR-9 genes family in human gastric adenocarcinoma.

Authors:  Raziyeh Ebrahimi-Askari; Mehrdad Behmanesh; Masoud Soleimani
Journal:  Mol Biol Res Commun       Date:  2015-06
View more
  1 in total

1.  Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of Helicobacter pylori: a randomized, double-blind clinical trial.

Authors:  Fariborz Mansour-Ghanaei; Alireza Samadi; Farahnaz Joukar; Hafez Tirgar Fakheri; Soheil Hassanipour; Mohammad Taghi Ashoobi; Soheil Soltanipour; Ahmad Alizadeh; Gholamreza Rezamand; Mohammad Fathalipour
Journal:  EXCLI J       Date:  2019-08-19       Impact factor: 4.068

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.